
MADARA: Updated Revenue Guidance

The management expects strong growth over the next three years

MADARA Cosmetics AS (hereafter 'MADARA' or the 'Company'), a leading Latvian producer of natural cosmetics and beauty products, announced its updated revenue guidance for the full year 2020 as well as for the next three years. According to the management, MADARA should end the current year on a strong note, generating total sales of c.a. EUR 16m, comfortably surpassing its earlier revenue guidance of EUR 15m for the year, while the new guidance for 2020 would mark nearly 40% annual growth in comparison with 2019. As a reminder, the Company is listed on the alternative market, Nasdag Baltic First North, and therefore publishes its full financial statements semiannually. However, MADARA has started quite progressive investor relation practices and normally also reports its quarterly revenues. The latest quarterly sales announcement revealed that the Company's Q3 2020 revenues increased by nearly 50% y-o-y to EUR 4.02m. The latest quarterly figures bring the total for the first nine months of 2020 to EUR 12.24m, corresponding to a solid 48% y-o-y expansion in sales. Although the Company has maintained strong sales growth throughout 2020, we should note that MADARA seems to experience somewhat larger quarterly volatility in its revenues this year compared to the previous year. Following a 25% y-o-y increase in sales in Q1 this year to EUR 3.2m, the top-line figure expanded sharply by 66% y-o-y in Q2 2020, to reach EUR 5.0m, presenting a new historic high. Considering the Q3 2020 number, following a 55% q-o-q rise recorded in Q2 2020, the Company's sales declined nearly 20% q-o-q in Q3 this year. Taking into account the reported 2020 quarterly revenue

MADARA's Quarterly Sales



Key Numbers (EURm)	2017	2018	2019	2020E	2021E	2022E
Sales (EURm)	7.4	9.5	11.5			
Sales growth (%)	26.3	28.7	21.2			
Net profit (EURm)	1.2	1.5	1.6			
EPS (EUR)	0.33	0.40	0.42			
P/E (x)	22.5	19.6	18.8			
Payout per share (EUR)#	0.05	0.09	0.12	Under review		,
Payout yield (%)	0.7	1.1	1.5			/
P/B (x)	3.9	3.5	3.1			
EV/Sales (x)	3.2	2.7	2.3			
EV/EBITDA (x)	13.5	13.0	12.0			
EV/EBIT (x)	17.7	17.6	17.8			
ROE (%)	24.6	19.3	17.4			

Source: MDARA

Source: MADARA

Company Profile

Listing Market:	First North Baltic Share List
Bloomberg Ticker:	MDARA LR
ISIN:	LV0000101624
Industry:	Consumer Goods
Sector:	Personal & Household Goods
No. of Employees:	148
Website:	www.madaracosmetics.com

Share Data, as of 21st Dec 2020

Current Share Price (EUR):	16.0
Fair Value Range (FVR), EUR:	U.R.
Downside, % (to mid-point of FVR):	n.a.
52-week High/Low (EUR):	19.50/6.50
3m Avg. Daily Volume (th):	0.27
Market Cap (EURm):	60.31
Ordinary Shares (m):	3.77

Key Shareholders, as of 30th June 2020

Uldis Iltners	24.08%
Lote Tisenkopfa-Iltnere	23.92%
Oy Transmeri Group AB	23.09%
Zane Tamane	7.61%
Liene Drāzniece	6.83%

12-Month Price Performance



LHV Fair Value Range:

Under review*

* Effective from 22nd Dec 2020



^{*}Payout per share include dividends and share capital reduction.

Baltic Review 22nd Dec 2020

numbers, the full-year sales target of EUR 16m would require Q4 2020 revenues of just EUR 3.8m, which is quite achievable, following the recent strong performance. We assume that Q4 2020 sales are negatively impacted by the new strong uptrend in COVID-19 infections and related movement restrictions imposed in Latvia and many other countries, considerably reducing footfall in physical stores. The Q4 2020 revenue guidance of EUR 3.8m would mean recording "only" c.a. 17% growth y-o-y, with the decline of c.a. 5% from the previous quarter.

The management also updated its longer-term view on the Company's sales dynamics. Considering MADARA's planned development activities and the growing brand recognition in the most important European markets, as well as the development potential of the natural cosmetics industry in general, the management targets to continue achieving growth of around 20% per year over the next

three years, with the total revenues reaching EUR 27m by 2023. The management indicated that rapidly expanding online sales play an important role in the Company's long-term strategy and developments. The proposed annual growth rate for 2021-2023 is much more ambitious than our latest projections for MADARA, but, considering the dynamics recorded in recent years, we believe such growth rates are not overly optimistic and should be quite achievable. Overall, we treat the Company's 2020 sales results and the new revenue guidance as encouraging signs about MADARA's ability to avoid any major setbacks due to the COVID-19 pandemic and successfully pursue its growth strategy with a stronger focus on e-commerce and finding new resellers in the Western Europe countries. Considering the recent news, we plan to review our financial projections and update the valuation.



Baltic Review 22nd Dec 2020

Contacts:

Ivars Bergmanis
Head of Institutional Markets
Tel: +372 680 2720
Mob: +372 534 11114

680 2720 Tel: +372 680 2793 2 534 11114 sander.danil@lhv.ee

Sander Danil

Senior Analyst

ivars.bergmanis@lhv.ee

Date and time of sign-off: Tuesday 22nd Dec, 17:00

Disclaimer

The copyright in this report belongs to AS LHV Pank (hereinafter 'LHV'). LHV is a full service bank with a focus on the Baltic region. LHV is a member of the Tallinn, Riga, and Vilnius stock exchanges. LHV is under the supervision of the Estonian Financial Supervisory Authority (Finantsinspektsioon; see also www.fi.ee).

Readers of this report should be aware of that LHV and LHV affiliated companies (hereinafter 'LHV's Group') are constantly seeking to offer investment banking services to companies (hereinafter, 'Company' or 'Companies') mentioned in research reports or may have other financial interests in those Companies.

AS LHV Pank has made an arrangement with AUGA group ('AUGA'), AB whereby LHV's research analysts independently produce research reports on AUGA group and provide them to AUGA for the purposes of providing more information about AUGA to investors who are not customers of LHV. In October 2019, AUGA group selected AS LHV Pank as an advisor as well as arranger and manager for a bond programme. The first tranche of such bonds were issued at the end of 2019.

AS LHV Pank has made an agreement with EfTEN Capital AS on commercial terms whereby LHV's research analysts independently produce research reports on EfTEN Real Estate Fund III. In turn, LHV is paid a fixed fee for a certain number of reports on an annual basis.

AS LHV Pank has made an arrangement with MADARA Cosmetics ('MADARA'), whereby LHV's research analysts independently produce research reports on MADARA and provide them to MADARA for the purposes of providing more information about MADARA to investors who are not customers of LHV. MADARA is listed on the NASDAQ Baltic First North List. LHV is also the certified adviser for LINDA on NASDAQ Baltic First North on an ongoing fee-based arrangement. In October 2019, AUGA group has selected AS LHV Pank as an advisor as well as arranger and manager for the contemplated bond issue. The first tranche of these bonds were issued and listed at the end of 2019. LHV was engaged as co-manager for the private placement of new units for Baltic Horizon Fund, announced in February 2019. LHV has also been engaged to explore capital raising possibilities for Valmieras Stikla Skiedra. LHV was the global coordinator for the Coop IPO in December 2019.

LHV's Group acts as a market maker /(and)/ liquidity provider for TKM1T, APG1L, TVEAT, OLF1R, HMX1R, LINDA, and MDARA.

All reports are produced by LHV's research department. In order to proactively prevent conflicts of interest, LHV has established several procedural and physical measures. Such measures include, among other things, confidentiality measures through separation, or so-called "Chinese walls", virtual and physical barriers to limit the exchange of information between different departments, groups or individuals within LHV Group. These measures are monitored by the compliance department of LHV. LHV does everything possible to avoid the conflict of interests but it cannot guarantee that conflict of interests situations do not arise at all.

LHV provides coverage on this company on a regular basis, therefore this report may include assumptions and findings laid out in greater detail elsewhere. If interested, clients may approach LHV for these previous reports.

This report is based upon information available to the general public. The information contained within has been compiled from sources deemed to be suitably reliable. However, no guarantee to that effect is given and henceforth neither the accuracy, completeness, nor the timeliness of this information should be relied upon. Any opinions expressed herein reflect a professional judgment of market conditions as at the date of publication of this document and are therefore subject to change without prior notice.

LHV reviews its estimates at least once during financial reporting period and upon most major financial events.

The report is not intended for public distribution and may not be reproduced, redistributed or published in any form whatsoever (in whole or in part) without prior written permission of LHV. The user shall be liable for any non-authorised reproduction or use of this report, whether in whole or in part, and such reproduction may lead to legal proceedings. LHV does not accept any liability whatsoever for the actions of third parties in this respect. This information



Baltic Review 22nd Dec 2020

may not be used to create any financial instruments or products or any indices.

Neither LHV nor its directors nor its representatives nor its employees will accept liability for any injuries, losses or damages, direct or consequential, caused to the reader that may result from the reader's acting upon or using the content contained in the publication.

The analyst(s) of this report hereby confirm that the views expressed in this report accurately reflect their personal views about the Companies and securities covered at the time of publication. The authors further confirm that they have not been, nor are nor will be receiving direct or indirect compensation in exchange for expressing any of the views contained in the report.

The analysts receive remuneration based on among others, the overall group revenues of LHV, including investment banking revenues. However, no compensation is based on a specific investment banking transaction. Trading with securities which are covered by a report is subject to strict compliance with internal rules governing own-account trading by staff members and third parties acting for the account of such staff members.

This research report is produced for the private information of recipients and LHV is not advising nor soliciting any action based upon it. If you are not a client of LHV, you are not entitled to this research report.

This report does not by any means constitute an offer or a solicitation, nor a recommendation to purchase or sell securities, commodities, currencies or other investments referred to herein.

This report does not constitute independent investment advice. LHV does not assume any fiduciary responsibility or liability for any consequence, financial or otherwise, arising from any investment or disinvestment decision taken on the basis of this report. It has been prepared without regard to the individual financial circumstances and objectives of those who receive this report. The securities referred to in this report may not be suitable for all investors.

Investors should independently and carefully evaluate every particular investment and seek the advice of a financial adviser if needed.

The analysis contained in this research report is based on numerous assumptions; different assumptions could result in materially different results. Any valuations, projections and forecasts contained in this report are based on a number of assumptions and estimates and are subject to contingencies and uncertainties. The inclusion of any such valuations, projections and forecasts in this report should not be regarded as a representation or warranty by or on behalf of LHV or any person within LHV that such valuations, projections and forecasts or their underlying assumptions and estimates will be met or realised.

Past performance is not a reliable indicator of future returns.

Where an investment is described as being likely to yield income, please note that the amount of income that the investor will receive from such an investment may fluctuate due to currency exchange rate moves and taxation considerations specific to that investor.

The information contained in this report does not constitute advice on the tax consequences of making any particular investment decision.

The fair value range has been issued for a 12-18 month period and has been derived from a weighted approach combining both DCF valuation and relative multiple comparisons. The relative multiple comparisons further incorporate additional weighting considerations relating to the underlying metrics and time forecast periods. Company specific inputs have been forecast and a list of peer companies has been compiled by the LHV analyst(s) writing this research commentary, whereas the consensus peer data has been obtained from Bloomberg. For more detailed information about the valuation methods please contact the analyst(s) using the contact details provided above.

For a useful summary of our coverage of this company, including the current sensitivity analysis, please refer to our latest monthly product: The Baltic Equity Companion. Alternatively you can also contact the analyst(s) using the contact details provided above.

Although we do not issue explicit recommendations, for regulation compliance purposes we adhere to the following synthetic structure:

- Buy- Expected return of more than 10% within 12-18 months (including dividends)
- Neutral- Expected return from -5% to 10% within 12-18 months (including dividends)
- Sell- Expected return less than -5% within 12-18 months (including dividends)

In the 12-month period preceding 01.04.2020 LHV has issued recommendations, of which 39.3% have been 'Buy' recommendations, 44.0% as 'Neutral', 4.8% as 'Sell' and 11.9% as 'under review'. Of all the 'Buy' recommendations issued, 15.2% have been for companies for which LHV has provided investment banking services in the preceding 12-month period. Of all the 'Neutral' recommendations issued, 13.5% have been issued to companies for which LHV has provided investment banking services in the preceding 12-month period. The classification is based on the above structure.

For a list of recommendations that were disseminated during the preceding 12-month period, including the date of dissemination, the identity of the person(s) who produced the recommendation, the price target and the relevant market price at the time of dissemination, the direction of the recommendation and the validity time period of the price target, please contact the analyst(s) using the contact details provided above.

